Lawrence, Donald P.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 5,231

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2,222

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 2,156

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology

Cancer Immunotherapy and BiomarkersViral Infections and Immunology Research

Cited by 1,608

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology

Brain Metastases and TreatmentCancer Immunotherapy and Biomarkers

Cited by 1,091

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 1,069

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,005

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma

Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 944

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 742

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 642

Bevacizumab plus ipilimumab in patients with metastatic melanoma

Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersAngiogenesis and VEGF in Cancer

Cited by 593

Phase I study of GC1008 (fresolimumab): a human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma

Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE

TGF-β signaling in diseasesCancer Immunotherapy and Biomarkers

Cited by 487

High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma

Faje, A. T., Lawrence, D., Flaherty, K., Freedman, C., Fadden, R., Rubin, K., Cohen, J., & Sullivan, R. J. (2018) · Cancer

Cancer Immunotherapy and BiomarkersAdrenal Hormones and Disorders

Cited by 486

MAP Kinase Pathway Alterations in BRAF -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 478

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas

Hong, D. S., Kurzrock, R., Supko, J. G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J. P., Meyer, C. J., Ferguson, D. A., et al. (2012) · Clinical Cancer Research

Genomics, phytochemicals, and oxidative stressBioactive Compounds and Antitumor Agents

Cited by 236

Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609

Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., et al. (2020) · Journal of Clinical Oncology

Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers

Cited by 184

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., et al. (2017) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersAngiogenesis and VEGF in Cancer

Cited by 164

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)

Lacouture, M. E., Morris, J. C., Lawrence, D. P., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Berzofsky, J. A., Hsu, F. J., & Guitart, J. (2015) · Cancer Immunology, Immunotherapy

Nonmelanoma Skin Cancer StudiesChemotherapy-related skin toxicity

Cited by 145